FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038494864> ?p ?o ?g. }

• W2038494864 endingPage "1021" @default.
• W2038494864 startingPage "1013" @default.
• W2038494864 abstract "Combination therapy with at least 2 antihypertensive agents is usually needed to achieve appropriate blood pressure (BP) control in patients with isolated or predominant systolic hypertension. A currently recommended combination is a diuretic added to an angiotensin-receptor blocker.This was a study of the effects on sitting systolic BP (SBP)of 2 combinations of valsartan and hydrochlorothiazide (HCTZ) compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension (SBP > or =160 mm Hg and < or =200 mm Hg) with or without other cardiovascular risk factors.After a placebo run-in period, patients were randomized to receive double-blind treatment with either valsartan 80 mg OD(monotherapy group) or valsartan 160 mg OD (combination-therapy groups) for 4 weeks, followed by forced titration to valsartan 160 mg OD (V160), valsartan 160 mg plus HCTZ 12.5 mg OD (V160 +HCTZ12.5), or valsartan 160 mg plus HCTZ 25 mg OD (V160 +HCTZ25) for an additional 4 weeks. End points were the change in SBP between the groups receiving combination therapy and the monotherapy group, between-group changes in diastolic BP (DBP), responder rates (SBP <140 mm Hg or a reduction in SBP of > or =20 mm Hg), and tolerability.A total of 774 patients were randomized to treatment: 261 to V160, 258 to V160+HCTZ12.5, and 255 to V160 +HCTZ25. The intent-to-treat population consisted of 767 patients (411 men, 356 women; mean age, 60 years; mean weight, 84 kg; clinic mean [SD] baseline BP, 167.5 [8.1]/93.4 [9.1] mm Hg). All treatments produced significant reductions in SBP from baseline (mean [SD] reduction, 20.7 [15.7] mm Hg with V160, 27.9 [13.8] mm Hg with V160 +HCTZ12.5, and 28.3 [13.1] mm Hg with V160+HCTZ25; all, P < 0.05). DBP was reduced by 6.6 (8.9) mm Hg in the V160 group and by 10.2 (7.7) and 10.1 (7.8) mm Hg in the V160+HCTZ12.5 and V160 +HCTZ25 groups, respectively (all, P < 0.05). The additional reductions in BP with V160+HCTZ25 did not reach statistical significance compared with V160+HCTZ12.5. Responder rates were 56.9% in the V160 group, 74.4% in the V160+HCTZ12.5 group, and 75.0% in the V160 +HCTZ25 group P < 0.05, combination therapy vs monotherapy). Adverse events were reported by 27.5% of patients in the monotherapy group, compared with 28.6% and 34.0% in the groups that received V160+HCTZ12.5 and V160+HCTZ25, respectively; the differences were not significant between treatment groups.Monotherapy with V160 was effective in these patients with stage 2 or 3 systolic hypertension. Significant additional reductions in SBP and DBP and an increase in responder rates were achieved with the addition to V160 of HCTZ12.5 and HCTZ25, with no significant effect on tolerability." @default.
• W2038494864 created "2016-06-24" @default.
• W2038494864 creator A5003871142 @default.
• W2038494864 creator A5007468017 @default.
• W2038494864 creator A5012918353 @default.
• W2038494864 creator A5022197187 @default.
• W2038494864 creator A5040528462 @default.
• W2038494864 creator A5044056736 @default.
• W2038494864 creator A5049307461 @default.
• W2038494864 date "2005-07-01" @default.
• W2038494864 modified "2023-09-30" @default.
• W2038494864 title "Antihypertensive Efficacy and Tolerability of Two Fixed-Dose Combinations of Valsartan and Hydrochlorothiazide Compared with Valsartan Monotherapy in Patients with Stage 2 or 3 Systolic Hypertension: An 8-Week, Randomized, Double-Blind, Parallel-Group Trial" @default.
• W2038494864 cites W148030191 @default.
• W2038494864 cites W2002502922 @default.
• W2038494864 cites W2026276739 @default.
• W2038494864 cites W2038031575 @default.
• W2038494864 cites W2048608125 @default.
• W2038494864 cites W2054108000 @default.
• W2038494864 cites W2057850517 @default.
• W2038494864 cites W2063675012 @default.
• W2038494864 cites W2133217116 @default.
• W2038494864 cites W2156121263 @default.
• W2038494864 cites W2159729565 @default.
• W2038494864 cites W2170912509 @default.
• W2038494864 cites W2171082420 @default.
• W2038494864 cites W2172032309 @default.
• W2038494864 cites W2413835975 @default.
• W2038494864 cites W2562329777 @default.
• W2038494864 cites W4246169631 @default.
• W2038494864 doi "https://doi.org/10.1016/j.clinthera.2005.07.010" @default.
• W2038494864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16154480" @default.
• W2038494864 hasPublicationYear "2005" @default.
• W2038494864 type Work @default.
• W2038494864 sameAs 2038494864 @default.
• W2038494864 citedByCount "63" @default.
• W2038494864 countsByYear W20384948642012 @default.
• W2038494864 countsByYear W20384948642013 @default.
• W2038494864 countsByYear W20384948642014 @default.
• W2038494864 countsByYear W20384948642015 @default.
• W2038494864 countsByYear W20384948642017 @default.
• W2038494864 countsByYear W20384948642019 @default.
• W2038494864 countsByYear W20384948642020 @default.
• W2038494864 countsByYear W20384948642021 @default.
• W2038494864 crossrefType "journal-article" @default.
• W2038494864 hasAuthorship W2038494864A5003871142 @default.
• W2038494864 hasAuthorship W2038494864A5007468017 @default.
• W2038494864 hasAuthorship W2038494864A5012918353 @default.
• W2038494864 hasAuthorship W2038494864A5022197187 @default.
• W2038494864 hasAuthorship W2038494864A5040528462 @default.
• W2038494864 hasAuthorship W2038494864A5044056736 @default.
• W2038494864 hasAuthorship W2038494864A5049307461 @default.
• W2038494864 hasConcept C126322002 @default.
• W2038494864 hasConcept C126894567 @default.
• W2038494864 hasConcept C142724271 @default.
• W2038494864 hasConcept C197934379 @default.
• W2038494864 hasConcept C204787440 @default.
• W2038494864 hasConcept C27081682 @default.
• W2038494864 hasConcept C2776999253 @default.
• W2038494864 hasConcept C2777387769 @default.
• W2038494864 hasConcept C2778375690 @default.
• W2038494864 hasConcept C2779918671 @default.
• W2038494864 hasConcept C2780361556 @default.
• W2038494864 hasConcept C2908647359 @default.
• W2038494864 hasConcept C71924100 @default.
• W2038494864 hasConcept C84393581 @default.
• W2038494864 hasConcept C99454951 @default.
• W2038494864 hasConceptScore W2038494864C126322002 @default.
• W2038494864 hasConceptScore W2038494864C126894567 @default.
• W2038494864 hasConceptScore W2038494864C142724271 @default.
• W2038494864 hasConceptScore W2038494864C197934379 @default.
• W2038494864 hasConceptScore W2038494864C204787440 @default.
• W2038494864 hasConceptScore W2038494864C27081682 @default.
• W2038494864 hasConceptScore W2038494864C2776999253 @default.
• W2038494864 hasConceptScore W2038494864C2777387769 @default.
• W2038494864 hasConceptScore W2038494864C2778375690 @default.
• W2038494864 hasConceptScore W2038494864C2779918671 @default.
• W2038494864 hasConceptScore W2038494864C2780361556 @default.
• W2038494864 hasConceptScore W2038494864C2908647359 @default.
• W2038494864 hasConceptScore W2038494864C71924100 @default.
• W2038494864 hasConceptScore W2038494864C84393581 @default.
• W2038494864 hasConceptScore W2038494864C99454951 @default.
• W2038494864 hasIssue "7" @default.
• W2038494864 hasLocation W20384948641 @default.
• W2038494864 hasLocation W20384948642 @default.
• W2038494864 hasOpenAccess W2038494864 @default.
• W2038494864 hasPrimaryLocation W20384948641 @default.
• W2038494864 hasRelatedWork W1978146008 @default.
• W2038494864 hasRelatedWork W1990346426 @default.
• W2038494864 hasRelatedWork W2031697972 @default.
• W2038494864 hasRelatedWork W2038494864 @default.
• W2038494864 hasRelatedWork W2049351459 @default.
• W2038494864 hasRelatedWork W2091249194 @default.
• W2038494864 hasRelatedWork W2156023625 @default.
• W2038494864 hasRelatedWork W2162991076 @default.
• W2038494864 hasRelatedWork W2407419780 @default.
• W2038494864 hasRelatedWork W94256357 @default.
• W2038494864 hasVolume "27" @default.
• W2038494864 isParatext "false" @default.

• next